Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Funding
Not specified
Deadline
--
Days
--
Hrs
--
Min
--
Sec
Jan 07, 2027
Posted Nov 18, 2024 (459 days ago)
Closes Jan 7, 2027 (in 320 days)
Grant Details
Opportunity Number
PAR-25-069
CFDA / ALN
93.393
Opportunity Category
Discretionary (D)
Funding Category
ED, HL
Funding Instrument
Grant (G)
Cost Sharing
No Cost Sharing (No)
Eligibility
State governments (00)
County governments (01)
City or township governments (02)
Special district governments (04)
Independent school districts (05)
Public and State controlled institutions of higher education (06)
Native American tribal governments (Federally recognized) (07)
Public housing authorities / Indian housing authorities (08)
Native American tribal organizations (11)
Nonprofits having a 501(c)(3) status with the IRS (12)
Nonprofits without 501(c)(3) status (13)
Private institutions of higher education (20)
For-profit organizations other than small businesses (22)
Small businesses (23)
Others (25)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Related Grants
Cooperative Agreement for affiliated Partner with the North Atlantic Coast Cooperative Ecosystem Studies Unit
Geological Survey
$498,392
New World Screwworm Grand Challenge
Animal and Plant Health Inspection Service
$5,000,000
FY 2026 National Infrastructure Investments
69A345 Office of the Under Secretary for Policy
$25,000,000
OVC FY25 Preventing Trafficking of Girls
Office for Victims of Crime
$497,000
OVC FY25 Specialized Human Trafficking Assistance: Supporting Survivor Engagement in Anti-Trafficking Programming
Office for Victims of Crime
$1,200,000
OVC FY25 Integrated Services for Minor Victims of Human Trafficking
Office for Victims of Crime
$950,000